EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non–Small-Cell Lung Cancer with EGFR Mutation

Kenichi Suda, Kazuko Sakai, Masaoki Ito, Hana Oiki, Shota Fukuda, Shuta Ohara, Akira Hamada, Masato Chiba, Masaki Shimoji, Kazuto Nishio, Yasuhiro Tsutani

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2026.03.002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Kenichi Suda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Sakai, Japan; Department of Thoracic Surgery, Izumi City …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tumor Suppressor Protein p53, RNA-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: RNA-binding motif 10 (RBM10) mutation in non-small-cell lung cancer (NSCLC) is associated with decreased sensitivity to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in vitro and in patients who received osimertinib as neoadjuvant treatment or palliative systemic therapy. The incidence of this mutation in early-stage NSCLC and the relationship with other mutations are unknown. MATERIALS AND METHODS: We analyzed the clinical and genomic data of 190 patients with NSCLC who underwent surgical resection between June 2022 and April 2024. Genomic data were obtained from whole-exome sequencing performed in an ongoing multicenter prospective observational study. RESULTS: RBM10 mutation was detected in 17 of 152 patients with nonsquamous NSCLC (11%) and not detected in 38 patients with squamous cell carcinomas. The incidences of RBM10 mutation were higher in tumors with EGFR mutation (21%) and tumors with KRAS mutation (12%) compared with those without EGFR/KRAS mutations (2%, P 76 years, P < .01), the presence of ground-glass opacity (P < 0.05), and histological grade 1 (P < .05). We observed mutually exclusive relationships between RBM10 mutation, TP53 mutation, and MDM2 gene amplification, and a high incidence of RBM10 mutation or MDM2 gene amplification in tumors with EGFR L858R mutation/uncommon mutation. CONCLUSION: RBM10 mutation is frequent in Japanese patients with NSCLC with EGFR mutation, especially those with L858R or uncommon mutations, and was associated with late-onset and features of indolent tumor growth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsTumor Suppressor Protein p53RNA-Binding ProteinsMutationHumansFemaleErbB ReceptorsMaleAgedMiddle AgedProspective StudiesProto-Oncogene Proteins c-mdm2Aged, 80 and overNeoplasm StagingAdult

Stichwörter der Autor:innen

Epidermal growth factor receptor (EGFR) mutationKRAS mutationMDM2 gene amplificationPersonalized treatmentRNA-binding motif protein 10 (RBM10)TP53 mutation

Substanzen

ErbB ReceptorsTumor Suppressor Protein p53RNA-Binding ProteinsEGFR protein, humanRBM10 protein, humanTP53 protein, humanProto-Oncogene Proteins c-mdm2MDM2 protein, human

Autor:innen und Institutionen

  • Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Sakai, Japan; Department of Thoracic Surgery, Izumi City General Hospital, Izumi, Japan. Electronic address: ksuda@med.kindai.a…
  • Department of Genome Biology, Kindai University Faculty of Medicine, Sakai, Japan.
  • Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Sakai, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Suda, K., Sakai, K., Ito, M., Oiki, H., Fukuda, S., Ohara, S., Hamada, A., Chiba, M., Shimoji, M., Nishio, K., & Tsutani, Y. (2026). Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non–Small-Cell Lung Cancer with EGFR Mutation. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.03.002

Vancouver

Suda K, Sakai K, Ito M, Oiki H, Fukuda S, Ohara S, et al. Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non–Small-Cell Lung Cancer with EGFR Mutation. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.03.002

BibTeX
@article{Suda2026,
  author = {Suda, Kenichi and Sakai, Kazuko and Ito, Masaoki and Oiki, Hana and Fukuda, Shota and Ohara, Shuta and Hamada, Akira and Chiba, Masato and Shimoji, Masaki and Nishio, Kazuto and Tsutani, Yasuhiro},
  title = {Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non–Small-Cell Lung Cancer with EGFR Mutation},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2026.03.002}
}
Kostenlos starten →